Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson’s disease
Objective: Verification of the previously reported association between chronic use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson’s disease (PD),…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy
Objective: Few reports describe experience with treatment of Parkinson's disease [PD] during pregnancy. About 5% of the population with PD are young onset (onset prior…Subacute Encephalopathy with Pimavanserin Treatment in Parkinson Disease
Objective: To report 3 cases of drug-induced encephalopathy in patients treated with pimavanserin (PVN) for Parkinson disease (PD) related psychosis (PDP). Background: Quetiapine and clozapine,…Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients
Objective: To evaluate the role of COMT gene variations on the pharmacokinetics (PK) of L-dopa in PD patients. Background: Genetic variations in enzymes (MAO-B, COMT),…Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC,…Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom
Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 34
- Next Page »